Enlivex Therapeutics Ltd. (ENLV)
Market Cap | 33.48M |
Revenue (ttm) | n/a |
Net Income (ttm) | -27.16M |
Shares Out | 18.60M |
EPS (ttm) | -1.47 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 14,702 |
Open | 1.78 |
Previous Close | 1.84 |
Day's Range | 1.78 - 1.86 |
52-Week Range | 1.27 - 4.65 |
Beta | 0.74 |
Analysts | Strong Buy |
Price Target | 12.00 (+566.67%) |
Earnings Date | Dec 12, 2023 |
About ENLV
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. En... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ENLV stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the ...

Enlivex to Present at the 2023 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management ...

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macropha...

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuan...

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
Nes-Ziona, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrop...

Enlivex Appoints Andrew Singer to its Board of Directors
Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appo...

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
NES-ZIONA, ISRAEL / ACCESSWIRE / April 14, 2023 / This month, H.C. Wainwright & Co. reiterated its buy rating for Enlivex Therapeutics Ltd.

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
NES-ZIONA, ISRAEL / ACCESSWIRE / April 12, 2023 / This month, Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced a new clinical collaboration agreement with Beigene Ltd to test a new combination treatm...

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
Nes-Ziona, Israel, April 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced its ful...

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a clinical c...

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
Nes-Ziona, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that an ...

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issua...

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that an i...

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
Nes-Ziona, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, on December 2, 2022 filed...

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Nes-Ziona, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the ...

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that comp...

Enlivex to Present at Upcoming Investor and Media Conferences
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Com...

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
Nes-Ziona, Israel, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macroph...

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Nes-Ziona, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that regu...

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
Nes-Ziona, Israel, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today filed with the SEC ...

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Nes-Ziona, Israel, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the ...

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macroph...

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Nes-Ziona, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macro...

Enlivex to Present at the 2022 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patient...